CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 200 target
Drug / intervention
ATGdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02643589
NCT02643589N/AUnknown
CompareCT.gov

Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis

Nanfang Hospital, Southern Medical University·interventional·Posted Dec 31, 2015·Updated Dec 31, 2015

In Brief

A clinical study evaluating ATG for Hematopoietic Stem Cell Transplantation. Targeting 200 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the incidences of GVHD in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. The investigators' first objective was to investigate the optimal dose of ATG for aGVHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematopoietic Stem Cell Transplantation
CountriesChina
CollaboratorsPeking University People's Hospital, Central South University Xiangya Hospital, Fujian Medical University

Timeline

N/AUnknownOverdue
2014201520162017201820192020202120222023202420252026
First PostedDec 31, 2015
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2016
Study CompletionDec 1, 2016
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 10.5 years ago

Interventions

ATGdrug

ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.